Growth Hormone Secretagogue
Hexarelin (Examorelin) Research Peptide
Hexarelin (INN: examorelin, CAS 140703-51-1) is a synthetic hexapeptide growth hormone secretagogue structurally related to GHRP-6 but with a 2-methyltryptophan substitution at position 2. It is among the most potent GHS-R1a agonists studied in preclinical and clinical research and has a distinct cardiovascular research profile.
Compound identity
- Name
- Hexarelin
- Class
- Growth Hormone Secretagogue
- CAS number
- 140703-51-1
- Molecular formula
- C47H58N12O6
- Also known as
- Examorelin, EP-23905, MF-6003
- Sequence
- His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2
Research context
Hexarelin has the sequence His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2 (CAS 140703-51-1, molecular formula C47H58N12O6, MW approximately 887.0 Da). The substitution of D-2-methyltryptophan at position 2 (compared to GHRP-6's D-tryptophan) confers increased metabolic stability and receptor binding potency at GHS-R1a. Hexarelin received the INN examorelin from WHO nomenclature and was developed by Europeptides. It was advanced to Phase III clinical trials for GH deficiency — making it one of the most clinically studied synthetic GHSR agonists alongside pralmorelin (GHRP-2).
Research on hexarelin encompasses GHS-R1a pharmacology, cardiovascular effects, and GH secretion dynamics. A body of preclinical work examined hexarelin's effects in ischemia-reperfusion injury models and reported cardioprotective findings in rodent hearts. The cardiac effects of hexarelin may involve mechanisms partially independent of the pituitary GHS-R1a, including proposed interactions with the CD36 scavenger receptor in cardiac tissue (described in research by Bodart, Beaumont, and colleagues). This dual pharmacology — pituitary GHS-R1a agonism plus potential cardiovascular effects through separate mechanisms — has made hexarelin a useful tool compound in cardiovascular research distinct from other GHSR agonists.
As a research reagent, hexarelin is used in receptor pharmacology studies, cardiovascular research models, and GH secretion studies. DMV Research supplies hexarelin as a lyophilized powder with per-batch third-party Certificate of Analysis confirming identity by MS and purity by HPLC to 99%+.
Frequently asked questions
What is hexarelin?+
Hexarelin (examorelin, CAS 140703-51-1) is a synthetic hexapeptide growth hormone secretagogue with the sequence His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2. It is structurally related to GHRP-6 with a 2-methyltryptophan substitution that increases receptor potency. It was developed by Europeptides and studied clinically under the INN examorelin.
How does hexarelin compare to GHRP-2 and GHRP-6?+
All three are GHS-R1a agonists. Hexarelin is generally considered more potent in receptor binding assays than the first-generation GHRP-6. Uniquely among this class, hexarelin has been studied for cardiovascular effects potentially mediated through mechanisms beyond GHS-R1a (including proposed CD36 interactions), giving it a distinct research application in cardiac biology.
Is hexarelin approved for human use?+
No. Despite progressing to Phase III clinical trials, hexarelin (examorelin) is not approved by the FDA or EMA for any indication. As supplied by DMV Research, it is for in-vitro and pre-clinical laboratory research use only.
What purity is the hexarelin research peptide?+
Each batch is tested by independent third-party laboratories to 99%+ purity by HPLC, with identity confirmed by mass spectrometry. A full Certificate of Analysis is available per batch.
Research use only
All products are intended for laboratory and research use only (RUO) and are not for human consumption, ingestion, or any in-vivo use.
The statements on this page have not been evaluated by the FDA. Hexarelin is not intended to diagnose, treat, cure, or prevent any disease. Content is provided for laboratory research reference only.